Non-Invasive Finger Cuff Devices for Continuous Arterial Pressure Monitoring
The commercially available non-invasive finger cuff devices using volume clamp technology are the Finometer (formerly Finapres), Portapres, ClearSight (Edwards Lifesciences), CNAP (Dräger Medical), and Nexfin (BMEYE), though these devices are primarily validated for research use rather than routine clinical care, and specific FDA clearances for patient populations are not detailed in the available guidelines. 1
Volume Clamp Technology Devices
Named Commercial Systems
The Penaz finger cuff method forms the technological basis for several commercial devices 1:
- Finometer (formerly called Finapres)
- Portapres - enables 24-hour ambulatory monitoring
- ClearSight (Edwards Lifesciences) 2, 3
- CNAP (Dräger Medical) 4, 2, 3
- Nexfin (BMEYE, Amsterdam) 5, 6
- Finapres NOVA 7, 8
How Volume Clamp Works
These devices operate on the "unloaded arterial wall" principle: a photoplethysmograph under a finger pressure cuff detects arterial pulsation, driving a servo-loop that rapidly adjusts cuff pressure to maintain the artery in a partially opened state. The cuff pressure oscillations resemble the intra-arterial pressure wave and can be maintained for up to 2 hours 1.
Tonometry-Based Devices
Wrist tonometry uses an array of transducers placed over the radial artery where it lies against the radius bone 1. The technique is highly position-sensitive and requires calibration for each patient, making it unsuitable for routine clinical use 1.
Peripheral arterial tonometry devices use thimble-like cups on fingertips to collect beat-to-beat plethysmographic recordings, analyzing pulse-wave amplitude changes before and after induced ischemia 9. However, these are primarily used for endothelial function assessment rather than continuous arterial line replacement.
Clinical Validation and Approved Populations
Critical Limitations for Clinical Use
The American Heart Association guidelines explicitly state that volume clamp finger cuff methods "in their present form are not suited to clinical use because of cost, inconvenience, and relative inaccuracy for measuring absolute levels of blood pressure." 1 Their greatest value is for research studies assessing short-term blood pressure changes and variability 1.
Accuracy Concerns
Volume clamp devices demonstrate:
- Moderate underestimation or overestimation of absolute blood pressure values compared to brachial artery pressures 1
- Better accuracy for tracking changes in systolic and diastolic pressure rather than absolute values 1
- Wide limits of agreement that compromise individual-level clinical decision-making 3, 8
Recent meta-analyses show that none of the volume clamp technologies (ClearSight, CNAP) met AAMI criteria for bias and standard deviation across mean arterial pressure, systolic, and diastolic measurements 3.
Specific Population Studies
Limited evidence exists for specific patient populations:
Left ventricular assist device patients: Finapres NOVA showed moderate correlation with arterial catheter measurements but may underestimate low BP and overestimate high BP, with only 40% of patients showing agreement within 5 mmHg 7
ICU patients: CNAP showed reasonable accuracy for mean and diastolic arterial pressure (22-28% error) but less accurate for systolic pressure (27% error) 4
Cardiac surgery patients: Nexfin demonstrated good correlation (0.93-0.96) and met AAMI criteria in adults 5, with a pediatric prototype showing promise in children but requiring further development 6
Pulmonary hypertension patients: Finapres NOVA showed acceptable group-level agreement but insufficient individual-level accuracy, with wide limits of agreement (-39.6 to 45.3 mmHg) 8
Common Pitfalls
Signal acquisition failures occur in 11-29% of patients, particularly with 2:
- Poor fingertip perfusion (capillary refill time >4 seconds)
- Hand edema
- Smaller children (single finger cuff size limitation) 9
When finger cuff monitoring fails or is unreliable, conventional oscillometric upper arm cuffs provide more reliable measurements and meet ISO standards 2.
Regulatory Status
The available evidence does not specify detailed FDA clearances for specific patient populations. The guidelines emphasize these devices are validated primarily for research applications rather than clinical arterial line replacement 1. The 2015-2025 ecosystem shows rapid progress toward cuffless-specific validation standards, but clinical utility remains dependent on intended use, population, calibration requirements, and clinical setting 10.